Qymune was selected from a competitive pool of applications and impressed the AbbVie team with the quality of their scientific data and high potential to achieve milestones set out in their scientific and entrepreneurial development. As a recipient of the Golden Ticket, Qymune will receive one sponsored bench at an MBC BioLabs facility, access to the wide-array of scientific equipment in its core labs, and access to business and scientific mentorship from leaders at AbbVie.

About Qymune
Qymune, formerly QUM Therapeutics, develops next-generation T cell engager (TCE) platforms designed to deliver powerful efficacy with unprecedented safety for patients. Our vision extends beyond oncology to autoimmune and other immune-driven diseases, where precisely removing pathogenic cells has the potential to fundamentally change patients’ lives. By combining deep immunology, antibody engineering, and cutting-edge science, we are reimagining the future of T cell engager therapies—with safety, precision, and durability at the core.

Learn more about Qymune on LinkedIn.